Primum non nocere: Adverse drug events must be taken seriously

Pharmacogenomics

Volumn 8, Issue 4, 2007, Pages 311-314

  Gurwitz, David ^a   McLeod, Howard L ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; AZATHIOPRINE; BIOLOGICAL MARKER; CLOPIDOGREL; CYCLOOXYGENASE 1; CYTOCHROME P450 2C11; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D1; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A5; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GLUTATHIONE TRANSFERASE M1; GLYCOPROTEIN VI; IBUPROFEN; MENADIONE EPOXIDE; MENADIONE EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; METFORMIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PARACETAMOL; PHENYTOIN; RISPERIDONE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; WARFARIN;

CLINICAL RESEARCH; DRUG DISPOSITION; DRUG INTOXICATION; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; EDITORIAL; ELECTRONIC MEDICAL RECORD; EMERGENCY HEALTH SERVICE; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PRACTITIONER; HEALTH SURVEY; HEMATOLOGY; HEREDITY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; KIDNEY; LIVER; MEDICATION ERROR; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SAFETY; PHARMACOGENETICS; PREDICTION; PRESCRIPTION; SEX DIFFERENCE; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; UNITED STATES;

EID: 34247151217     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.4.311     Document Type: Editorial

References (20)

1. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL: National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296, 1858-1866 (2006).
2. Pirmohamed M, James S, Meakin S et al.: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329, 15-19 (2004).
3. Dormann H, Neubert A, Criegee-Rieck M et al.: Readmissions and adverse drug reactions in internal medicine: the economic impact. J. Intern. Med. 255, 653-663 (2004).
4. Otero Lopez MJ, Alonso Hernandez P, Maderuelo Fernandez JA, Ceruelo Bermejo J, Dominguez-Gil Hurle A, Sanchez Rodriguez A: Prevalence and factors associated with preventable adverse drug events leading to hospital admission. Farm. Hosp. 30, 161-170 (2006).
5. Queneau P, Bannwarth B, Carpentier F et al.; on behalf of Association Pedagogique Nationale pour l'Enseignement de la Therapeutique (APNET): Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf. 30, 81-88 (2007).
6. Schnipper JL, Kirwin JL, Cotugno MC et al.: Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch. Intern. Med. 166, 565-571 (2006).
7. Davidson A: Preventing adverse drug events. CMAJ 176, 67-68 (2007).
8. Leonard MS, Cimino M, Shaha S, McDougal S, Pilliod J, Brodsky L: Risk reduction for adverse drug events through sequential implementation of patient safety initiatives in a children's hospital. Pediatrics 118, E1124-E1129 (2006).
9. Young D: Electronic system alerts pharmacists to potential adverse drug events. Am. J. Health Syst. Pharm. 58, 2362-2365 (2001).
10. Hurdle JF, Weir CR, Roth B, Hoffman J, Nebeker JR: Critical gaps in the world's largest electronic medical record: ad hoc nursing narratives and invisible adverse drug events. AAMIA Annu. Symp. Proc. 309-312 (2003).
11. Pezalla E: Preventing adverse drug reactions in the general population. Manag. Care Interface 18, 49-52 (2005).
12. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 356(9242), 1667-1671 (2000).
13. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270-2279 (2001).
14. Beitelshees AL, McLeod HL: Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. Trends Pharmacol. Sci. 27, 498-502 (2006).
15. Lunshof JE, Pirmohamed M, Gurwitz D: Personalized medicine: decades away? Pharmacogenomics 7, 237-241 (2006).
16. Kollek R, van Aken J, Feuerstein G, Schmedders M: Pharmacogenetics, adverse drug reactions and public health. Community Genet. 9, 50-54 (2006).
17. Voora D, Eby C, Linder MW et al.: Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb. Haemost. 93, 700-705 (2005).
18. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
19. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. DOI 10.1038/ sj.tpj.6500417 (2006) [Epub ahead of print].
20. Grown C, Gupta GR, Pande R: Taking action to improve women's health through gender equality and women's empowerment. Lancet 365, 541-543 (2005).